Drug major Lupin today said it has received US health regulator's approval to market a generic version of Sanofi Aventis' Rifadin capsules, used to treat tuberculosis, in the American market.
The company's US-based subsidiary Lupin Pharmaceuticals Inc has received final approval from US Food and Drug Administration (USFDA) for its Rifampin Capsules in 150 mg and 300 mg strengths, Lupin Ltd said in a statement.
Rifampin Capsules are indicated for the treatment of all forms of tuberculosis.
As per the IMS sales data, Rifadin Capsules had annual US sales of around $18.5 million.
"Lupin is one of the pioneers in the fight against Tuberculosis and holds global leadership positions in the Anti-TB segment," the Mumbai-based firm said.
Shares in Lupin, on Friday, ended at Rs 790.30 apiece on the BSE, up 1.55 per cent from the previous close.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
